Proteomics

Dataset Information

0

Human colon cancer cell lines - LC-MSMS


ABSTRACT: Despite the advent of mutant-selective KRAS inhibitors, colorectal cancer (CRC) responses remain limited, with frequent stable disease and rapid recurrence. The mechanisms underlying CRC tolerance to KRAS inhibition and eventual resistance are poorly understood. Here, we explored early transcriptional and proteomic changes following KRAS silencing in 3D CRC spheroid models to identify pathways linked to sensitivity or resistance. Based on growth, cell cycle, and apoptosis responses, cell lines were classified as KRAS silencing-sensitive (HCT116, SW480) or -resistant (LS174T, SW837). Sensitive cells showed upregulation of the unfolded protein response (UPR) and WNT/β-catenin signaling, while these pathways were downregulated in resistant cells. Proteomic analysis confirmed UPR deregulation, with reduced translation-related proteins in sensitive cells. Functional assays revealed that KRAS knockdown in HCT116 reduced protein aggregation and translational capacity, consistent with UPR activation. However, inhibiting IRE1α-mediated UPR signaling did not reverse KRAS silencing-induced arrest or apoptosis. These findings suggest UPR activation as an early adaptive response in KRAS-dependent CRC cells.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture, Colon

DISEASE(S): Colon Cancer

SUBMITTER: Rune Matthiesen  

LAB HEAD: Rune Matthiesen

PROVIDER: PXD059013 | Pride | 2025-05-07

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
BagSV_10_1.raw Raw
BagSV_10_2.raw Raw
BagSV_11_1.raw Raw
BagSV_11_2.raw Raw
BagSV_12_1.raw Raw
Items per page:
1 - 5 of 50
altmetric image

Publications

Differential unfolded protein response regulation in KRAS silencing sensitive and innately resistant colorectal cancer cells.

Martins Flávia F   Machado Ana L AL   Carvalho Joana J   Almeida Catarina R CR   Beck Hans C HC   Carvalho Ana S AS   Backman Vadim V   Matthiesen Rune R   Velho Sérgia S  

Scientific reports 20250424 1


Despite the development of mutant-selective KRAS inhibitors, colorectal cancer (CRC) responses remain limited, with stable disease and rapid recurrence being common outcomes. The molecular mechanisms enabling CRC cells to tolerate KRAS inhibition and ultimately develop resistance remain poorly understood. Here, we investigated early transcriptional and proteomic responses to KRAS silencing in 3D CRC cell line spheroid models, aiming to identify pathways associated with sensitivity or resistance  ...[more]

Similar Datasets

2024-02-06 | GSE254833 | GEO
2024-02-06 | GSE254832 | GEO
2024-12-12 | GSE283752 | GEO
2022-07-24 | E-MTAB-11953 | biostudies-arrayexpress
2022-09-30 | E-MTAB-12041 | biostudies-arrayexpress
2023-04-21 | E-MTAB-12753 | biostudies-arrayexpress
2024-08-12 | MSV000095581 | MassIVE
2025-03-01 | PXD054525 | Pride
2004-09-20 | E-MEXP-100 | biostudies-arrayexpress
2023-12-15 | GSE250118 | GEO